Ani Pharmaceuticals (ANIP) Gross Profit (2012 - 2026)

Ani Pharmaceuticals has disclosed Gross Profit across 15 years of filings, most recently posting $165.9 million for Q2 2026.

• In Q2 2026, Gross Profit rose 21.3% year-over-year to $165.9 million; the TTM figure through Jun 2026 stood at $591.0 million (up 29.49% YoY), while the FY2025 annual figure was $542.1 million, up 48.85% from the prior year.
• Gross Profit came in at $165.9 million for Q2 2026 at Ani Pharmaceuticals, up from $143.9 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $165.9 million in Q2 2026 to a low of $30.2 million in Q1 2022.
• Average Gross Profit over 5 years is $94.4 million, with a median of $84.5 million recorded in 2023.
• Year-over-year, Gross Profit fell 12.54% in 2022 and soared 128.69% in 2023.
• Over 5 years, Gross Profit stood at $57.9 million in 2022, then jumped by 35.11% to $78.2 million in 2023, then surged by 40.98% to $110.3 million in 2024, then jumped by 33.09% to $146.8 million in 2025, then gained by 13.01% to $165.9 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $165.9 million in Q2 2026, $143.9 million in Q1 2026, and $146.8 million in Q4 2025.